Meeting of Dermatologic and Ophthalmic Drugs Advisory Committee Announcement | oneGRAVESvoice

welcome to oneGRAVESvoice

- a positively charged Graves' disease and thyroid eye disease community.
  • join today!

Meeting of Dermatologic and Ophthalmic Drugs Advisory Committee Announcement

The committee will discuss biologics license application (BLA) 761143, teprotumumab solution for intravenous use, submitted by Horizon Pharma Ireland, Ltd., proposed for the treatment of active thyroid eye disease.

The public participation information has been changed for the December 13, 2019 Meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee. The deadline for making formal oral presentation requests has been changed from Tuesday, November 26, 2019 to Monday, December 2, 2019. The deadline for submitting electronic or written comments to be provided to the committee has been changed from Wednesday, December 4, 2019 to Monday, December 9, 2019.


Date & Time:

December 13, 2019

8:00 AM to 4:00 PM



FDA White Oak Campus

10903 New Hampshire Avenue

Building 31 Conference Center

The Great Room (Rm. 1503)

Silver Spring, Maryland, United States


This event has ended.


Meeting Of Dermatologic And Ophthalmic Drugs Advisory Committee Announcement
Font Resize

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.